Uptake of Respiratory Syncytial Virus Prefusion F Protein Vaccination during Pregnancy and nirsevimab among Infants over Two Seasons in a Single Health System.
- 1Division of General Academic Pediatrics, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh.
- 2University of Pittsburgh School of Medicine, Pittsburgh.
Abstract
Objective
To describe the uptake of respiratory syncytial virus (RSV) prevention products during the first 2 seasons after availability in the US in a large health system.Study design
Using multisource immunization data from a single health system, we identified a retrospective cohort of infants born from October 2023 to April 2024 (season 1) and from September 2024 to April 2025 (season 2) and their birth parents. We described the uptake of RSV prefusion F protein (RSVpreF) vaccination and nirsevimab and evaluated factors associated with receipt using multivariable logistic regression.Results
Among 10 196 infants, 5868/10 196 (57.6%) were exposed to an RSV-preventive product. Overall, in our maternal-infant dyads, 3850/10 196 (37.8% of total) received RSVpreF, 1837/10 196 infants (18.0% of total) received nirsevimab, and in 181/10 196 (1.8%), both were received. Uptake increased from 2100/4555 (46.1%) in season 1 to 3768/5641 (66.8%) in season 2 (P < .001). Maternal RSVpreF vaccination increased from 1280/4555 (28.1%) to 2570/5641 (45.6%), and nirsevimab uptake increased from 749/4555 (16.4%) to 1088/5641 (19.3% both P < .001). Nirsevimab receipt at <6 days of life increased from 242/749 (32.2%) to 502/1088 (46.1%, P < .001). RSVpreF uptake was higher among older, privately insured pregnant individuals and those engaged in other preventative care and lower among those with higher area deprivation, more complex obstetric histories, or other children. Nirsevimab uptake was higher among infants with prematurity or from multifetal births and lower among those with siblings, later-season birth, or no early outpatient care. Social and structural disparities in nirsevimab uptake improved in the second season, whereas disparities in RSVpreF uptake persisted.Conclusions
The uptake of RSV preventive strategies increased across 2 seasons, with a higher uptake of maternal RSVpreF vaccination than nirsevimab.
Related
- Maternal Vaccination vs Nirsevimab Use and Respiratory Syncytial Virus Infection Among Full-Term Infants
- Efficacy, Effectiveness, and Immunogenicity of the Respiratory Syncytial Virus Prefusion F Vaccine Administered During Pregnancy: Protocol for a Living Systematic Review and Meta-Analysis.
- Respiratory syncytial virus vaccination during pregnancy confers higher anti-RSV IgG concentration in neonatal cord than maternal blood
- A randomised, double-blind, multicentre, placebo-controlled phase 3 efficacy, safety, and immunogenicity study of an Ad26.RSV.preF/RSV prefusion F-protein vaccine for the prevention of respiratory syncytial virus-mediated lower respiratory tract disease in adults aged 60 years and older
- Assessing the Effects of Nirsevimab on Respiratory Syncytial Virus Bronchiolitis Outcomes: Insights From A Two‐Season Analysis
BibTeX
@article{kerr2026uptake,
title = {{Uptake of Respiratory Syncytial Virus Prefusion F Protein Vaccination during Pregnancy and nirsevimab among Infants over Two Seasons in a Single Health System.}},
author = {Jessica E Kerr and Annaliese J Calzadilla and Hui Liu and Anne-Marie Rick},
journal = {Journal of pediatrics. Clinical practice},
year = {2026},
month = sep,
doi = {10.1016/j.jpedcp.2026.200241},
url = {https://europepmc.org/article/MED/42909243},
note = {CC BY},
}
RIS
TY - JOUR
TI - Uptake of Respiratory Syncytial Virus Prefusion F Protein Vaccination during Pregnancy and nirsevimab among Infants over Two Seasons in a Single Health System.
AU - Jessica E Kerr
AU - Annaliese J Calzadilla
AU - Hui Liu
AU - Anne-Marie Rick
PY - 2026
DA - 2026/09/15
JO - Journal of pediatrics. Clinical practice
DO - 10.1016/j.jpedcp.2026.200241
UR - https://europepmc.org/article/MED/42909243
AB - Objective To describe the uptake of respiratory syncytial virus (RSV) prevention products during the first 2 seasons after availability in the US in a large health system.Study design Using multisource immunization data from a single health system, we identified a retrospective cohort of infants born from October 2023 to April 2024 (season 1) and from September 2024 to April 2025 (season 2) and their birth parents. We described the uptake of RSV prefusion F protein (RSVpreF) vaccination and nirsevimab and evaluated factors associated with receipt using multivariable logistic regression.Results Among 10 196 infants, 5868/10 196 (57.6%) were exposed to an RSV-preventive product. Overall, in our maternal-infant dyads, 3850/10 196 (37.8% of total) received RSVpreF, 1837/10 196 infants (18.0% of total) received nirsevimab, and in 181/10 196 (1.8%), both were received. Uptake increased from 2100/4555 (46.1%) in season 1 to 3768/5641 (66.8%) in season 2 (P < .001). Maternal RSVpreF vaccination increased from 1280/4555 (28.1%) to 2570/5641 (45.6%), and nirsevimab uptake increased from 749/4555 (16.4%) to 1088/5641 (19.3% both P < .001). Nirsevimab receipt at <6 days of life increased from 242/749 (32.2%) to 502/1088 (46.1%, P < .001). RSVpreF uptake was higher among older, privately insured pregnant individuals and those engaged in other preventative care and lower among those with higher area deprivation, more complex obstetric histories, or other children. Nirsevimab uptake was higher among infants with prematurity or from multifetal births and lower among those with siblings, later-season birth, or no early outpatient care. Social and structural disparities in nirsevimab uptake improved in the second season, whereas disparities in RSVpreF uptake persisted.Conclusions The uptake of RSV preventive strategies increased across 2 seasons, with a higher uptake of maternal RSVpreF vaccination than nirsevimab.
SN - 2950-5410
ER -